Short answer
Nuvectis Pharma, Inc. (NVCT) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$6M
- −13.5% YoY
- EPS (diluted)
- −$0.26
- +3.7% YoY
Source: XBRL data from the Nuvectis Pharma, Inc. (NVCT) Q1 2026 10-Q on SEC EDGAR. USD.
Nuvectis Pharma, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no revenue generated through March 31, 2026
- Operating margin not applicable; operating loss $6.3M vs $5.6M YoY
- R&D expenses $4.1M vs $3.7M, driven by manufacturing costs of $829K
- Cash $25.1M; operating cash use $6.5M vs $4.2M YoY
- Outlook: expenses expected to increase substantially; capital projected to fund operations at least 12 months
Risk Factors
- Newly added trade-policy risk: tariffs could increase raw-material and laboratory-equipment costs; no operational impact identified as of March 31, 2026
- Most material development risk: NXP800 development ceased in platinum-resistant ARID1a-mutated ovarian carcinoma after preliminary Phase 1b analysis
- Regulatory risk: FDA or agency disruptions could delay product reviews and restrict public-market access during government shutdowns
- Near-term operational risk: CRO or CMO underperformance could delay NXP900’s Phase 1b clinical trial
- Financial risk: accumulated deficit reached $105.7 million through March 31, 2026, with substantial additional funding required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvectis Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.